Research reveals MBOAT7 and CDS2 impact lipid droplet size and cholesterol metabolism in MASLD, suggesting key regulatory pathways.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 20%-25% of the global population. A common genetic variant, rs641738, in the membrane-bound O-acyltransferase 7 (MBOAT7) gene, is strongly associated with disease progression. However, the physiological function and regulatory mechanisms of MBOAT7 remain incompletely understood. Lipid droplet (LD) accumulation is a hallmark of MASLD. In this study, we reveal a coordinated role of MBOAT7 and CDP-diacylglycerol synthase 2 (CDS2) in regulating LD size and cholesterol metabolism. Under normal conditions, CDS2 interacts with MBOAT7 at the endoplasmic reticulum (ER). In the absence of CDS2, however, MBOAT7 relocates to ER-LD contact sites in a RAB1-dependent manner, where it competes with DGAT2 for RAB1 binding. This competition inhibits LD expansion and promotes lipolysis. This MBOAT7-mediated LD size reduction activates the AMPK-LXR axis, enhancing cholesterol excretion, while loss of MBOAT7 or CDS2 disrupts this pathway, leading to hepatic cholesterol accumulation. Together, our study identifies a CDS2-MBOAT7-RAB1 regulatory axis controlling LD homeostasis and cholesterol metabolism.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: